Citations

Clear

29 citation(s) found for "Marks, Randolph".

Phase III Comparison of Twice-Daily Split-Course Irradiation Versus Once-Daily Irradiation for Patients With Limited Stage Small-Cell Lung Carcinoma
Bonner, James A. , Sloan, Jeff A. , Shanahan, Thomas G., Brooks, Burke J., Marks, Randolph S., Krook, James E., Gerstner, James B., Maksymiuk, Andrew W., Levitt, Ralph, Mailliard, James A., Tazelaar, Henry D. , Hillman, Shauna L., Jett, James R., Tazelaar, Henry D.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 17 | Issue: 9 | Pages: 2681-2681

10.1200/jco.1999.17.9.2681 | PMID 10561342 Get It

PURPOSE: Because small-cell lung cancer is a rapidly proliferating tumor, it was hypothesized that it may be more responsive to thoracic irradiation (TI) given twice-daily than once-daily. This hypothesis was tested in a phase III trial. PATIENTS AND METHODS: Patients with limited-stage small-cell lung cancer were entered onto a phase III trial, and all patients initially received three cycles of etoposide (130 mg/m 2 × 3) and cisplatin (30 mg/m 2 × 3). Subsequently, patients who did not have progression to a distant site (other than brain) were randomized to twice-daily thoracic irradiation (TDTI) versus once-daily thoracic irradiation (ODTI) given concomitantly with two additional cycles of etoposide (100 mg/m 2 × 3) and cisplatin (30 mg/m 2 × 3). The irradiation doses were TDTI, 48 Gy in 32 fractions, with a 2.5-week break after the initial 24 Gy, and ODTI, 50.4 Gy in 28 fractions. After thoracic irradiation, the patients received a sixth cycle of etoposide/cisplatin, followed by prophylactic cranial irradiation (30 Gy/15 fractions) if they had a complete response. RESULTS: Of 311 assessable patients enrolled in the trial, 262 underwent randomization to TDTI or ODTI. There were no differences between the two treatments with respect to local-only progression rates, overall progression rates, or overall survival. The patients who received TDTI had greater esophagitis (≥ grade 3) than those who received ODTI (12.3% v 5.3%; P = .05). Although patients received thoracic irradiation encompassing the postchemotherapy volumes, only seven of 90 local failures were out of the portal of irradiation. CONCLUSION: When TI is delayed until the fourth cycle of chemotherapy, TDTI does not result in improvement in local control or survival compared with ODTI.
S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results
Pisters, Katherine M.W., Bunn, Paul, Crowley, John, Ginsberg, Robert J., Ellis, Peter , Meyers, Brandon M. , Marks, Randolph S., Treat, Joseph, Gandara, D., Vallières, Eric , Gandara, David R.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: LBA7012-LBA7012

10.1200/jco.2005.23.16_suppl.lba7012 Get It

A pooled analysis of 11 NCCTG advanced stage non-small cell lung cancer (NSCLC) trials reveals the importance of baseline blood counts on clinical outcomes
Mandrekar, Sumithra J. , Hillman, Shauna L., Foster, Nathan R. , Adjei, Alex A. , Marks, Randolph S., Mailliard, J A, Krook, James E., Maksymiuk, Andrew W., Jett, James R., Schild, Steven E.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 7193-7193

10.1200/jco.2005.23.16_suppl.7193 Get It

A phase III randomized placebo controlled NCCTG trial of carboxyaminoimidazole (CAI) in patients with advanced non-small cell lung cancer (NSCLC)
Marks, Randolph S., Mandrekar, Sumithra J. , Hillman, Shauna L., Mailliard, J A, Dentchev, Todor, Reuter, Nicholas F., Jett, James R., Perez, Edith A. , Johnson, Elizabeth Anne

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 7054-7054

10.1200/jco.2005.23.16_suppl.7054 Get It

A phase I study of BAY 43–9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)
Adjei, Alex A. , Mandrekar, Sumithra J. , Marks, Randolph S., Hanson, L., Aranguren, Dawn, Jett, James R., Simantov, Ronit, Croghan, Gary A., Schwartz, Brian E.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3067-3067

10.1200/jco.2005.23.16_suppl.3067 Get It

A phase I trial of the combination of erlotinib and tipifarnib in patients with advanced solid tumors
X., C., Croghan, Gary A., Hanson, L., Mandrekar, Sumithra J. , Marks, Randolph S., Adjei, Alex A. , Furth, Alfred, Reid, Joel M.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3000-3000

10.1200/jco.2005.23.16_suppl.3000 Get It

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study
Chee, Cheng E. , Ashrani, Aneel A. , Marks, Randolph S., Petterson, Tanya M. , Bailey, Kent R. , Melton, L. Joseph, Heit, John A.

Mayo Clinic

Blood | April 29, 2014 | Volume: 123 | Issue: 25 | Pages: 3972-3978

10.1182/blood-2014-01-549733 | PMID 24782507 Get It

Key Points VTE recurrence risk in patients with cancer can be stratified by cancer type, stage, stage progression, and presence of leg paresis. Patients with cancer at high VTE recurrence risk should be considered for secondary prophylaxis.
Genome-Wide Association Study of Genetic Predictors of Overall Survival for Non–Small Cell Lung Cancer in Never Smokers
Wu, Xifeng , Ye, Yuanqing , Aakre, Jeremiah A. , Chang, Gee-Chen , Yang, Pan‐Chyr , Roth, Jack A. , Marks, Randolph S., Lippman, Scott M. , Deschamps, Claude, Su, Wu‐Chou , Wang, Wen‐Chang , Huang, Ming‐Shyan , Chang, David W. , Hong, Waun Ki , Hsiung, Chao A. , Wang, Liang , Pu, Xia , Chang, Joe Y. , Lu, Charles , Li, Yan , Pankratz, V. Shane , Minna, John Dorrance , Hildebrandt, Michelle A.T. , Yang, Ping

Mayo Clinic

Cancer Research | May 24, 2013 | Volume: 73 | Issue: 13 | Pages: 4028-4038

10.1158/0008-5472.can-12-4033 | PMID 23704207 Get It

Abstract To identify the genetic factors that influence overall survival in never smokers who have non–small cell lung carcinoma (NSCLC), we conducted a consistency meta-analysis study using genome-wide association approaches for overall survival in 327 never smoker patients with NSCLC from The University of Texas MD Anderson Cancer Center (Houston, TX) and 293 cases from the Mayo Clinic (Rochester, MN). We then conducted a two-pronged validation of the top 25 variants that included additional validation in 1,256 patients with NSCLC from Taiwan and assessment of expression quantitative trait loci (eQTL) and differential expression of genes surrounding the top loci in 70 tumors and matched normal tissues. A total of 94 loci were significant for overall survival in both MD Anderson and Mayo studies in the consistency meta-analysis phase, with the top 25 variants reaching a P value of 10−6. Two variants of these 25 were also significant in the Taiwanese population: rs6901416 [HR, 1.44; 95% confidence interval (CI), 1.01–2.06] and rs10766739 (HR, 1.23; 95%CI, 1.00–1.51). These loci resulted in a reduction of median survival time of at least eight and five months in three populations, respectively. An additional six variants (rs4237904, rs7976914, rs4970833, rs954785, rs485411, and rs10906104) were validated through eQTL analysis that identified significant correlations with expression levels of six genes (LEMD3, TMBIM, ATXN7L2, SHE, ITIH2, and NUDT5, respectively) in normal lung tissue. These genes were also significantly differentially expressed between the tumor and normal lung tissue. These findings identify several novel, candidate prognostic markers for NSCLC in never smokers, with eQTL analysis suggesting a potential biologic mechanism for a subset of these observed associations. Cancer Res; 73(13); 4028–38. ©2013 AACR.
Screening for Lung Cancer with Low-Dose Spiral Computed Tomography
Swensen, Stephen J., Jett, James R., Sloan, Jeff A. , Midthun, David E. , Hartman, Thomas E. , Sykes, Anne-Marie , Aughenbaugh, Gregory L., Zink, Frank E., Hillman, Shauna L., NOETZEL, GAYLE R., Marks, Randolph S., Clayton, Amy C., Pairolero, Peter C.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 4, 2013 | Volume: 165 | Issue: 4 | Pages: 508-513

10.1164/ajrccm.165.4.2107006 | PMID 11850344 Get It

Abstract Studies suggest that screening with spiral computed tomography can detect lung cancers at a smaller size and earlier stage than chest radiography can. To evaluate low-radiation-dose spiral computed tomography and sputum cytology in screening for lung cancer, we enrolled 1,520 individuals aged 50 yr or older who had smoked 20 pack-years or more in a prospective cohort study. One year after baseline scanning, 2,244 uncalcified lung nodules were identified in 1,000 participants (66%). Twenty-five cases of lung cancer were diagnosed (22 prevalence, 3 incidence). Computed tomography alone detected 23 cases; sputum cytology alone detected 2 cases. Cell types were: squamous cell, 6; adenocarcinoma or bronchioalveolar, 15; large cell, 1; small cell, 3. Twenty-two patients underwent curative surgical resection. Seven benign nodules were resected. The mean size of the non-small cell cancers detected by computed tomography was 17 mm (median, 13 mm). The postsurgical stage was IA, 13; IB, 1; IIA, 5; IIB, 1; IIIA, 2; limited, 3. Twelve (57%) of the 21 non-small cell cancers detected by computed tomography were stage IA at diagnosis. Computed tomography can detect early-stage lung cancers. The rate of benign nodule detection is high.
Genetic Variants Associated with the Risk of Chronic Obstructive Pulmonary Disease with and without Lung Cancer
Marks, Randolph S., Deschamps, Claude, Scanlon, Paul D., Olswold, Curtis L., Jiang, Ruoxiang , Swensen, Stephen J., Sun, Zhifu , Cunningham, Julie M. , Wampfler, Jason A. , Midthun, David E. , Andrade, Mariza de , Li, Yan , Limper, Andrew H. , Yang, Ping , Sun, Zhifu

Mayo Clinic

Cancer Prevention Research | November 1, 2011 | Volume: 5 | Issue: 3 | Pages: 365-373

10.1158/1940-6207.capr-11-0243 | PMID 22044695 Get It

Abstract Chronic obstructive pulmonary disease (COPD) is a strong risk factor for lung cancer. Published studies about variations of genes encoding glutathione metabolism, DNA repair, and inflammatory response pathways in susceptibility to COPD were inconclusive. We evaluated 470 single-nucleotide polymorphisms (SNP) from 56 genes of these three pathways in 620 cases and 893 controls to identify susceptibility markers for COPD risk, using existing resources. We assessed SNP- and gene-level effects adjusting for sex, age, and smoking status. Differential genetic effects on disease risk with and without lung cancer were also assessed; cumulative risk models were established. Twenty-one SNPs were found to be significantly associated with risk of COPD (P < 0.01); gene-based analyses confirmed two genes (GCLC and GSS) and identified three additional genes (GSTO2, ERCC1, and RRM1). Carrying 12 high-risk alleles may increase risk by 2.7-fold; eight SNPs altered COPD risk without lung cancer by 3.1-fold and 4 SNPs altered the risk with lung cancer by 2.3-fold. Our findings indicate that multiple genetic variations in the three selected pathways contribute to COPD risk through GCLC, GSS, GSTO2, ERCC1, and RRM1 genes. Functional studies are needed to elucidate the mechanisms of these genes in the development of COPD, lung cancer, or both. Cancer Prev Res; 5(3); 365–73. ©2011 AACR.